Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Leukemia
|
February 13, 2009
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
V H J Van der Velden, L Corral, M G Valsecchi, et al.
Leukemia
|
November 15, 2011
Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia
E Ellinghaus, M Stanulla, G Richter, et al.
Lancet (London, England)
|
December 16, 1998
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
J J van Dongen, T Seriu, E R Panzer-Grümayer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 17, 2021
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol
J Stutterheim, P de Lorenzo, I M van der Sluis, et al.
Leukemia
|
May 4, 2007
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements
J Saldanha, M Silvy, N Beaufils, et al.
Leukemia
|
October 30, 2013
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome
C J Harrison, A V Moorman, C Schwab, et al.
Leukemia
|
July 24, 2015
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study
J M Boer, A van der Veer, D Rizopoulos, et al.
Leukemia
|
March 13, 2019
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
H Pfeifer, G Cazzaniga, V H J van der Velden, et al.
Leukemia
|
January 16, 2020
Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
H Pfeifer, G Cazzaniga, V H J van der Velden, et al.
Leukemia
|
April 5, 2023
The KMT2A recombinome of acute leukemias in 2023
C Meyer, P Larghero, B Almeida Lopes, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Leukemia
|
February 13, 2009
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
V H J Van der Velden, L Corral, M G Valsecchi, et al.
Leukemia
|
November 15, 2011
Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia
E Ellinghaus, M Stanulla, G Richter, et al.
Lancet (London, England)
|
December 16, 1998
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
J J van Dongen, T Seriu, E R Panzer-Grümayer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 17, 2021
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol
J Stutterheim, P de Lorenzo, I M van der Sluis, et al.
Leukemia
|
May 4, 2007
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements
J Saldanha, M Silvy, N Beaufils, et al.
Leukemia
|
October 30, 2013
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome
C J Harrison, A V Moorman, C Schwab, et al.
Leukemia
|
July 24, 2015
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study
J M Boer, A van der Veer, D Rizopoulos, et al.
Leukemia
|
March 13, 2019
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
H Pfeifer, G Cazzaniga, V H J van der Velden, et al.
Leukemia
|
January 16, 2020
Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
H Pfeifer, G Cazzaniga, V H J van der Velden, et al.
Leukemia
|
April 5, 2023
The KMT2A recombinome of acute leukemias in 2023
C Meyer, P Larghero, B Almeida Lopes, et al.
Page
of 7